Product name

Cytoprotective erythropoietin variants

Summary

Novel endogenous variants of erythropoietin and their use for treatment or prevention of a condition associated with tissue damage due to cell death and inflammation.

Organization name

IPAL GmbH

Profile

For the application of EPO to prevent tissue damage the haematopoietic activity is often not required and might be detrimental if large amounts of EPO are administered to treat or ameliorate the effects of hypoxia or ischemia induced tissue damage. Therefore, attempts have been made to create EPO variants, which only exhibit the cell protective property but not the haematopoietic properties.

However, all presently known EPO variants having a decreased haematopoietic activity suffer from the disadvantage that they are not naturally occurring since they have either lost their natural glycosylation or they are artificial truncations and/or they have vastly diminished cell protective activity, if compared to rhEPO.

The EPO variants described here are advantageous, because

1. they are endogeneous and are therefore expected to have pharmacokinetic and pharmacodynamic advantages as well as a good tolerability;
2. their smaller size compared to unmodified EPO suggests an even smoother passage of the blood brain barrier;
3. they have demonstrated better tissue protecting activity than rhEPO but less or no haematopoietic, in particular no erythropoietic, activity in vitro.

Advantages

• Novel EPO variants that show stronger cyto-/neuroprotection than human recombinant EPO in vitro
• Complete lack of erythropoietic activity
• Easier passage of the blood-brain barrier due to smaller molecular size is expected
• Pharmacokinetic & -dynamic advantages and potentially reduced risk of immunological neutralization due to endogenous origin
• Only few cyto-/neuroprotective agents with no EPO relation are registered
• Big expected market potential

European and PCT patent applications have been filed.

The technology was developed at the Charité (Berlin/Germany) and is offered by IPAL.

IPAL GmbH 
Dr. Christian Wunsch 
christian.wunsch(at)ipal.de

About IPAL 

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.

Description File

 05022_Cytoprotective_EPO_variants_TA.pdf

URL

http://www.ipal.de/en/technology_offers/life_sciences/

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney